Thermo Fisher Scientific: Assessing Valuation After SHL Medical Alliance and US Capacity Expansion

Thermo Fisher Scientific's share price has declined 17.5% YTD, but its fair value is estimated at $540.27, according to the most followed narrative. The company's recurring revenue model, adoption of AI in life sciences, and automation in laboratories contribute to its valuation. However, biotech and pharma R&D budget tightening or weaker than expected integration benefits from large acquisitions like PPD could impact the narrative.